CLINICAL_TRIALS
trial_result
· 2018-04-13
Clinical Trial Update: A Study of Subcutaneous Bevacizumab in Relapsed / Progressive Glioblastoma [Phase 2]
Summary
Phase 2 study evaluating subcutaneous bevacizumab for relapsed or progressive glioblastoma; results were posted in 2018.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Emory University | Conditions: Glioblastoma | Phase 2 | Status: COMPLETED | Results posted: 2018-04-13